Anthera says final Phase IIb data back blisibimod despite earlier failure
This article was originally published in Scrip
Executive Summary
Anthera Pharmaceuticals believes the final set of clinical data from the Phase IIb PEARL-SC study with blisibimod in patients with systemic lupus erythematosus add fuel to its argument that despite the trial failing to meet its primary endpoint, the results are sufficient to pursue the product into Phase III.